AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

As FDA Adds Major Approval To Diabetes Drug's Label

AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.

AZ
Flags out at AZ after key Farxiga approval • Source: Shutterstock

Now that AstraZeneca PLC’s diabetes drug Farxiga has got a game-changing approval for heart failure in the US, the company believes indication-based pricing makes sense for the SGLT2 inhibitor given its potential for keeping thousands of patients out of hospital.

The US Food and Drug Administration approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalization in adults...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip